𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment

✍ Scribed by Sally Hopkins-Donaldson; Richard Cathomas; A. Paula Simões-Wüst; Stefanie Kurtz; Larisa Belyanskya; Rolf A. Stahel; Uwe Zangemeister-Wittke

Publisher
John Wiley and Sons
Year
2003
Tongue
French
Weight
317 KB
Volume
106
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Our study was designed to investigate the role of the anti‐apoptotic proteins Bcl‐2 and Bcl‐xL in the chemoresistance of cells derived from malignant pleural mesothelioma. First, we determined the basal expression levels of Bcl‐2 and Bcl‐xL in mesothelioma cells and examined the effect of their downregulation by antisense oligonucleotides. Bcl‐xL mRNA and protein could be readily detected in mesothelioma cell lines, whereas only low levels of Bcl‐2 mRNA and protein were found. Preferential downregulation of either Bcl‐xL alone or of Bcl‐xL and Bcl‐2 simultaneously was achieved by treatment with antisense oligonucleotides 4259 and 4625, respectively, whereas the expression of other apoptosis‐relevant genes remained unaffected. Treatment with oligonucleotides 4259 or 4625 lowered the apoptosis threshold in ZL34 mesothelioma cells, as indicated by an increase in cell death accompanied by increased caspase‐3‐like activity, a decrease of the mitochondrial transmembrane potential and the cleavage of procaspase‐7 and ICAD. In addition to the direct induction of apoptosis, antisense treatment sensitized ZL34 cells to the cytostatic effect of cisplatin and gemcitabine, with the combination of 4625 and cisplatin being the most effective. Our results demonstrate that Bcl‐2 and Bcl‐xL antisense treatment facilitates apoptosis in mesothelioma cells and suggest the use of Bcl‐2/Bcl‐xL bispecific antisense treatment in combination with cisplatin or gemcitabine for therapy of malignant pleural mesothelioma. © 2003 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Induction of apoptosis in lung-cancer ce
Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment
✍ Siân H. Leech; Robert A. Olie; Oliver Gautschi; A. Paula Simões-Wüst; Stefan Tsc 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 239 KB 👁 1 views

Over-expression of the anti-apoptotic protein bcl-xL is frequently found in lung cancer where it potentially contributes to tumor development, progression and drug resistance. To override the apoptotic block in lung-adenocarcinoma and small-cell-lung-cancer (SCLC) cells caused by over-expression of

Bcl-xl antisense oligonucleotides induce
Bcl-xl antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine
✍ Zhong-wei Xu; Helmut Friess; Marc Solioz; Stefan Aebi; Murray Korc; Jörg Kleeff; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 245 KB

Pancreatic cancer is one of the leading causes of cancerrelated death in Western countries. Bcl-x L is an anti-apoptotic factor of the Bcl-2 family, which is overexpressed in pancreatic cancer and its presence correlates with shorter patient survival. In this study, sequence-specific antisense oligo

Bcl-xL and Bcl-2 expression in squamous
Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck
✍ John C. Pena; Craig B. Thompson; Wendy Recant; Everett E. Vokes; Charles M. Rudi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 234 KB 👁 2 views

## Background: Inhibition of apoptosis, or programmed cell death, may be critical both in the development of cancer and in determining response to therapy. the authors examined the expression of two related apoptotic inhibitors, bcl-2 and bcl-xl, in pretreatment biopsies from a series of 42 patient